| |
April 3-4, 2023 | San Diego, CA The only west coast event exclusively for life science communicators to share best practices, benchmarks, and tools, as well as network with peers. Early Bird Rate Ends January 27th. 
|
|
Today's Big NewsJan 27, 2023 |
| By Max Bayer Goldfinch Bio, a 2020 Fierce Biotech Fierce 15 winner, is closing its doors after seven years. Federal records show that both of the company's ongoing clinical trials have wrapped up. |
|
|
|
By Angus Liu Merck & Co.’s Keytruda won the FDA’s permission to enter early-stage disease with an approval that trumps Roche’s Tecentriq. But there are two small caveats. |
By Dave Muoio The scheme allowed those who paid up to $15,000 to sit for an exam and potentially be employed as a nurse without the required coursework or clinicals, DOJ said. Some customers are actively working in healthcare today. |
By Andrea Park For the second quarter of its fiscal year 2023, ResMed reached $1.03 billion in revenues, marking its highest-ever quarterly haul. |
|
Thursday, February 16, 2023 | 11am ET / 8am PT Join this session as a panel of experts discusses the realized benefits of using AI and communication tools to redefine the care pathway to detect stroke and streamline the patient journey to direct more patients for cardiology follow-up. Register now. 
|
|
By James Waldron British biotech IPOs in 2022 dropped to their lowest levels in a decade, with the amount the sector raised also plummeting year over year. However, some hope may be on the horizon in the form of billions of pounds in fresh VC funds. |
By Kevin Dunleavy Two Bristol Myers Squibb employees who were fired for refusing to be vaccinated against COVID-19 have agreed to settlements, court documents show. A third fired employee who also sued has had her case dismissed. |
By Robert King CMS approved a first-of-its-kind waiver to allow California to offer Medicare coverage for beneficiaries who are incarcerated in a bid to improve care coordination. |
By Andrea Park Synchron and Elon Musk’s Neuralink are currently leading the brain-computer interface pack, but a potential competitor has emerged complete with tens of millions of dollars in financing and a former Neuralink executive at the helm. |
By Nick Paul Taylor Celgene spinout Celularity has left an ax dangling over a “substantial portion” of its workforce. While the cell therapy firm is “hopeful” it can avoid significant layoffs, it has told many staffers their jobs are on the line as it pursues an updated strategy. |
By Angus Liu The closely watched CARTITUDE-4 trial testing J&J and Legend Biotech's Carvykti in earlier myeloma has hit its goal at an interim analysis, bringing the CAR-T battle against Bristol Myers Squibb to a new level. But experts expect the drug to clear a high bar to call the trial a practice-changing win. |
By Paige Minemyer Humana is bringing its CenterWell clinics to the Dallas-Fort Worth region, with plans to open 10 locations across the market over the course of this year. |
By Conor Hale Researchers at King’s College London have found that a blood test can help predict a person’s risks of Alzheimer’s disease years before a clinical diagnosis, by evaluating the body’s ability to form new brain cells. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we hear from Stacie Dusetzina, Ph.D., a professor at Vanderbilt University's Department of Health Policy, about what the IRA means for the pharma industry. We'll also discuss what we can expect from the biotech industry in 2023. |
|
|---|
|
|
|
Tuesday, February 7, 2023 | 11am ET / 8am PT This session will focus upon understanding your knowns and unknowns, best practices for mitigating risk and addressing the specific drug supply challenges commonly associated with adaptive, decentralized, platform and other complex trial designs. Register now. 
|
|
Whitepaper RCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| May 1-3, 2023 | Jersey City, NJ |
|
|
| |
|
